DFMO treatment decreased the levels of the two eIF5As in three breast cancer cell lines, whereas the expression level of eIF5A2 in MCF7 cells was very low, and a DMFO-induced reduction was not observed (Fig. 3A). This evidence concerns the gene EIF5A2 and breast cancer.